Account
Insider Insights
18.10.2022
UK Agencies join with International HTA Partners f...

A cross-border alliance of health technology assessment (HTA) agencies has been announced by the Can...

Read more
Publications
12.10.2022
ISPOR 2022: Do manufacturers still see value in su...

Our research is aimed at identifying trends in terminated appraisals in relation to therapeutic area...

Read more
News
24.08.2022
PMA Insights: Week 34

We summarise key pharmaceutical, pricing and market access insights that are worth reading about thi...

Read more
News
27.07.2022
PMA Insights Week 30

We summarise key pharmaceutical, pricing and market access insights that are worth reading about thi...

Read more
Insider Insights
19.07.2022
NICE provides detail on Early Value Assessment

NICE provided more detail into how the process will work, with the early value assessments providing...

Read more
News
14.07.2022
PMA Insights: Week 28

We summarise key pharmaceutical, pricing and market access insights that are worth reading about thi...

Read more
Insider Insights
13.07.2022
NICE expands access of Tremfya in England and Wale

The HTA initially recommended Tremfya as a treatment option for adults with active psoriatic arthrit...

Read more
News
29.06.2022
PMA Insights: Week 26

We summarise key pharmaceutical, pricing and market access insights that are worth reading about thi...

Read more
Insider Insights
23.06.2022
NICE publish their new real world evidence framewo

NICE have been clear that this framework should not be interpreted as minimum standards for real-wor...

Read more
Insider Insights
20.06.2022
NICE trials new proportionate approach to increase

The aim of this trial is to increase capacity, with a goal of a 20% increase by 2023-24.

Read more

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.